Unidentified Participant: Good morning. This is Sean on for Balaji. Thanks for taking our question. On a recent tornado damage to the Pfizers Rocky Mount facility, what level of impact do you see this event could potentially have on the sterile injectable market? And as we think about pushing potential shortages here, do you see any specific opportunities in a sterile injectable market from this incident for Viatris. Thank you.
Rajiv Malik: Yes. First of all, really unfortunate event, nobody anticipated it, but having said, we have stayed very close to the market. We have stayed close to our customers. We have stayed close to FDA from the drug shortages point-of-view, we have some overlap products with Pfizer’s portfolio coming out of the Rocky Mount facility. And look, if there is a need as we are seeing those customers we will step-up, we are working very closely with the supply chain to make sure that we are in a position to address the drug shortages as and when if they come through.
Operator: Thank you. We’ll take our next question from Nathan Rich with Goldman Sachs.
Nathan Rich: Great. Good morning, thanks for taking the questions. First, you noted the generics business came in ahead of expectations. It seems like the new product launch guidance wasn’t changed and maybe base business erosion was a bit better than you had anticipated. Can you just maybe talk about what you’re seeing there? There’s obviously been a lot in the news on product shortages, have you seen stabilization or firming of generic pricing in that business? And then as a follow-up. I wanted to ask on gross margin. Could you just go into a bit more detail on what’s driving the step-down in the back half of the year and where you’d expect the gross margin to be for the full year within the guidance range that you have? Thank you.
Rajiv Malik: So, Nate, let me take the first part and second I’ll have Sanjeev respond to that. The first, overall, from our — just let me talk first globally. First, the base business. We have — as I said in my prepared remarks, we have — we see the momentum we have seen never before and our base business, whether it’s in emerging markets or China or Europe or North America, yes, it’s hitting on all cylinders. So, the stability and predictability of seeing we have never seen before. So, it’s setting up the company exactly how we have planned it and how we’ve seen it, the execution is just bringing this to the whole another level now. So, having said that from the generics point-of-view, generics across, not only just US, see I’ll come to the US specifically because I know your question was about the USA.
But even in emerging markets in Europe, generics you had a very solid performance. In fact, 11% or 10% growth in emerging markets was largely also driven by the generic performance. In the US, we always knew that the pricing is a factor of — two factors. It’s one either, demand and supply, and the second is your portfolio mix. Now on portfolio mix, we have diligently worked, moved away from commodities, more diversified complex products, and that’s given up that’s part of the underlying stability of the mix in the USA. Demand and Supply, yes, the market is seeing some disruption, the market is seeing some hiccups and it may go a little bit further in that direction. We may see more supply disruptions before it comes better and because of the slight disruptions, because of the diversity we have seen price stabilization over the last several quarters in the North America, which we have not seen for a few years back.
So, yes, we see the market conditions improving as well as — [indiscernible] as well as generics are concerned.
